Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06624098

Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma

Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma With Main Trunk Portal Vein Tumor Thrombus Induced Gastrointestinal Bleeding: a Multicenter Phase II Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
22 (estimated)
Sponsor
Sun Yat-sen University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension. Studies have proven that early transjugular intrahepatic portosystemic shunt (TIPS) with 72 hours after acute variceal bleeding is effective.

Detailed description

Portal hypertension by main trunk portal vein tumor thrombus (PVTT) is a severe disease. Patients usually die of gastrointestinal hemorrhage rather than tumor progression. It is vital to prevent the portal hypertension. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective method to alleviate the portal pressure. Then the risk of gastrointestinal hemorrhage is decreased which provides an opportunity for system therapy. Studies have proven that early transjugular intrahepatic portosystemic shunt (TIPS) with 72 hours after acute variceal bleeding is effective for cirrhosis induced portal hypertension. However, the PVTT induced portal hypertension still needs clinical evidence. In this study, the investigators explore the early TIPS for advanced hepatocellular carcinoma with main trunk portal vein tumor thrombus induced acute variceal bleeding. The investigators aim to added clinical evidence for this subtype of advanced HCC.

Conditions

Interventions

TypeNameDescription
PROCEDUREEarly TIPSTIPS was performed within 72 hours after the endoscopic hemostasis.

Timeline

Start date
2024-10-01
Primary completion
2025-12-30
Completion
2026-06-30
First posted
2024-10-02
Last updated
2024-10-02

Locations

2 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06624098. Inclusion in this directory is not an endorsement.